文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-PSMA放射配体治疗晚期前列腺癌的疗效及其与临床参数的关系:单中心经验

Outcome of 177 Lu-PSMA Radionuclide Treatment in Advanced Prostate Cancer and Its Association With Clinical Parameters : A Single-Center Experience.
PubMed 文献 · Clin Nucl Med · 2022-05-11

该单中心回顾性研究纳入100例接受至少1个周期177Lu-PSMA-617治疗的进展性转移性去势抵抗性前列腺癌(mCRPC)患者,中位年龄未报告,中位PSA为75.7 ng/mL,中位治疗周期数为3(范围1-9)。首次周期后生化部分缓解、稳定和进展分别占31%、36%和33%,任何PSA下降见于60%患者;第四次周期后分别为48%、26%和26%。中位总生存期(OS)为14个月,首次周期后有任何PSA应答者OS显著长于无应答者(17 vs 9个月,P≤0.001)。

要点

  • 首次周期后任何PSA下降见于60%患者,生化部分缓解31%、稳定36%、进展33%。
  • 第四次周期后生化部分缓解48%、稳定26%、进展26%。
  • 中位OS为14个月,首次周期后有PSA应答者OS显著长于无应答者(17 vs 9个月,P≤0.001)。

核心结论

  • LuPSMA治疗对mCRPC患者疗效显著且毒性率低,即使在接受标准治疗后仍进展的患者中也是如此。
  • 基线PSMA肿瘤负荷、PSA、碱性磷酸酶、乳酸脱氢酶和血红蛋白是OS的显著预测因素,可用于筛选最适合LuPSMA治疗的患者。

研究设计与样本

  • 单中心回顾性研究,纳入100例接受至少1个周期177Lu-PSMA-617治疗的进展性mCRPC患者。
  • 疗效依据前列腺癌临床试验工作组3(PCWG3)生化应答标准判定,毒性依据CTCAE v4.03定义。
  • 采用SPSS Version 24.0分析实验室/临床数据及68Ga-PSMA PET/CT定量结果的预后意义。

主要发现

  • 患者中位PSA为75.7 ng/mL,中位治疗周期数为3(范围1-9)。
  • 首次周期后生化部分缓解、稳定和进展分别占31%、36%和33%;任何PSA下降见于60%患者。
  • 第四次周期后生化部分缓解、稳定和进展分别占48%、26%和26%。
  • 自首次周期起中位OS为14个月;首次周期后有PSA应答者中位OS为17个月,无应答者为9个月(P≤0.001)。
  • 单因素Cox回归中,总PSMA肿瘤体积(P=0.004)、总PSMA活性/病灶(P=0.01)、PSA(P=0.007)、碱性磷酸酶(P=0.002)、乳酸脱氢酶(P<0.001)和血红蛋白(P<0.001)是OS的显著预后因素。

关键数值与推荐

  • 生化应答采用前列腺癌临床试验工作组3(PCWG3)标准判定。
  • 毒性分级采用CTCAE v4.03标准定义。

临床怎么用

  • 作者认为,LuPSMA治疗对mCRPC患者具有显著疗效和低毒性率,即使患者在接受标准治疗后仍进展。
  • 作者认为,基线PSMA肿瘤负荷、PSA、碱性磷酸酶、乳酸脱氢酶和血红蛋白是OS的显著预测因素,可用于筛选最适合LuPSMA治疗的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study was set out to analyze the efficacy and safety of 177 Lu-PSMA-617 (LuPSMA) treatment in metastatic castration-resistant prostate cancer (mCRPC) patients. PATIENTS AND METHODS: Progressive mCRPC patients who received at least 1 cycle of LuPSMA therapy were evaluated retrospectively. Demographic, clinic, and histopathological data were documented. Treatment efficacy was determined based on biochemical response criteria (Prostate Cancer Clinical Trial Working Group 3), and toxicity rates were defined based on CTCAE v4.03. The prognostic significance of laboratory/clinical data and 68 Ga-PSMA PET/CT quantitative results were analyzed using SPSS Version 24.0. RESULTS: One hundred patients (median prostate-specific antigen [PSA] level, 75.7 ng/mL) who met the eligibility criteria were identified. The median number of cycles received per patient was 3 (range, 1-9). After the first cycles of LuPSMA, biochemical partial response, biochemical stable disease, and biochemical progressive disease were observed in 31%, 36%, and 33% of patients, respectively. Any PSA decline was determined in 60% of patients. After the fourth cycle of treatment, biochemical partial response, biochemical stable disease, and biochemical progressive disease were defined in 48%, 26%, and 26% of patients, respectively. The median overall survival (OS) from the first cycle of LuPSMA was 14 months. Patients who had any PSA response after the first cycle had significantly longer OS than nonresponders (median OS: 17 vs 9 months; P ≤ 0.001). Total PSMA-derived tumor volume ( P = 0.004), total PSMA activity per lesion ( P = 0.01), PSA ( P = 0.007), alkaline phosphatase ( P = 0.002), lactate dehydrogenase ( P < 0.001), and hemoglobin ( P < 0.001) were significant prognostic factors for OS in univariate Cox regression analysis. CONCLUSIONS: LuPSMA therapy is a favorable treatment for mCRPC with remarkable therapeutic efficacy and low toxicity rates, even in progressive disease under standard therapies. Baseline PSMA-based tumor burden, PSA, alkaline phosphatase, lactate dehydrogenase, and hemoglobin were significant predictors of OS and can be useful for selection of the best candidate for LuPSMA therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Has Simsek D, Kuyumcu S, Karadogan S, et al. Outcome of 177 Lu-PSMA Radionuclide Treatment in Advanced Prostate Cancer and Its Association With Clinical Parameters : A Single-Center Experience. Clin Nucl Med. 2022. PMID: 35543629. doi:10.1097/RLU.0000000000004222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。